Impact of the amount and composition of dietary fat and carbohydrate on metabolic syndrome and cardiovascular disease risk

ISRCTN ISRCTN29111298
DOI https://doi.org/10.1186/ISRCTN29111298
Protocol serial number NO2031
Sponsor MRC Human Nutrition Research (UK)
Funder Food Standards Agency (UK)
Submission date
16/08/2005
Registration date
19/09/2005
Last edited
23/08/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Susan Jebb
Scientific

MRC Human Nutrition Research
Elsie Widdowson Laboratory
Fulbourn Road
Cambridge
CB1 9NL
United Kingdom

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific title
Study acronymRISCK
Study objectivesTo test whether the replacement of saturated fat (SFA) with monounsaturated fat (MUFA), compared with carbohydrate (CHO), will result in improved insulin sensitivity in adults with features of the metabolic syndrome; and whether CHO quality will influence the relative health impact of both the MUFA-rich and CHO-rich diet regimens.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedMetabolic syndrome and cardiovascular disease risk
InterventionComparison of four experimental diets (high MUFA, high glycemic index [GI]; high MUFA, low GI; low fat, high GI; low fat, low GI) with a control group (SFA intake typical of the UK habitual diet)
Intervention typeDrug
PhaseNot Specified
Drug / device / biological / vaccine name(s)Saturated fat (SFA), monounsaturated fat (MUFA), carbohydrate (CHO)
Primary outcome measure(s)

Insulin sensitivity from measures of glucose and insulin during an intravenous glucose tolerance test.

Key secondary outcome measure(s)

1. Fasting lipid profile
2. Vascular reactivity and endothelial function
3. Haemostatic factors
4. Markers of the inflammatory response
5. Leptin and adiponectin
6. Urinary microalbumin to creatinine ratio
7. Plasma fatty acid composition
8. DNA for nutrient-gene interactions

Completion date31/12/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexAll
Target sample size at registration650
Key inclusion criteriaMales and females, 30-70 years and at higher metabolic risk (based on a composite scoring system for metabolic syndrome features).
Key exclusion criteria1. History of the following conditions/treatments
1.1. myocardial infarction
1.2. cancer
1.3. diabetes mellitus
1.4. cholestatic liver disease or pancreatitis
1.5. chronic coronary, renal or bowel disease
1.6. gastrointestinal disorders
1.7. hypolipidemic therapy
1.8. systemic corticosteroids
1.9. androgens
1.10. phenytoin
1.11. erythromycin
1.12. heamostatic drugs (excluding aspirin)
2. Smokers >20/day
3. History of substance abuse or alcoholism
4. Pregnancy, planning pregnancy or 12-months post-partum
5. Allergy or intolerance to study foods
6. Recent weight change
7. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) >1 g/day
Date of first enrolment01/01/2004
Date of final enrolment31/12/2007

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

MRC Human Nutrition Research
Cambridge
CB1 9NL
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/08/2009 Yes No
Results article results 01/10/2010 Yes No
Results article results 01/12/2011 Yes No
Results article results 01/02/2012 Yes No
Results article results 01/09/2013 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes
Study website Study website 11/11/2025 11/11/2025 No Yes